The results from a large phase 3 human clinical trial led by pharmaceutical company Eli Lilly have been released, but unfortunately the results weren’t as positive as the research team were hoping.
The trial, called EXPEDITION3 involved more than 2,100 people diagnosed with mild dementia due to Alzheimer’s disease, who were testing the efficacy of a drug called Solanezumab.
Solanezumab has been studied for many years now and is an experimental antibody therapy which targets clumps of amyloid beta proteins in the brain and renders them non-functioning. The aim of the therapy is to reduce and remove amyloid toxicity, thus avoiding neuronal cell damage.
In EXPEDITION3, participants received the therapy for more than 18 months and results were compared with those who received a placebo treatment.
“The results of the Solanezumab EXPEDITION3 trial were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer’s disease,” said Dr John Lechleiter, Chairman, President and CEO of Lilly.
Unfortunately, the specifics of the trial were not made available online, but what we do know is that participants who were given the Solanezumab therapy failed to show enough improvements in cognition for the therapy to be considered successful. As such, Eli Lilly decided not continue to trial this therapy in people with Alzheimer’s disease.
While results like this are disappointing, not all is lost. All experimental results add to medical research realm and with them can come improvements to future treatments and important outcomes for other scientists and companies who may be working on alternative treatments. It is also worth noting that some other clinical trials are still in progress which are trialling Solanezumab as a preventative treatment rather than a disease modifying therapy – so watch this space!
Also, other large scale human trials, testing other amyloid beta antibody therapies are still in progress and there is still hope that results from these trials will provide positive outcomes.
Please share with your readers the very positive results and announcement from Anavex regarding theri 41 Week Phase 2a results for A2-73. I don't understand how a company may report the first Regression Free Survival in Mild to moderate Alzheimre's Patients and no major Alzheimer Foundation report it? Their Phase 2 Testing is ongoing in Australia even! They announce 1 Year Data on Dec 10,2016 at CTAD.